Finch Therapeutics Group announced the appointment of Matthew P. Blischak as Chief Executive Officer, effective May 16, 2023. In conjunction with the appointment of Mr. Blischak, Mark Smith, PhD, will conclude his role as Chief Executive Officer and as a member of the Company’s board of directors, effective May 15. Dr. Smith is expected to remain engaged with the Company as a scient strategic advisor. In addition, Finch announced the appointment of Lance Thibault as Chief Financial Officer, effective May 16. In conjunction with the appointment of Mr. Thibault, Marc Blaustein will conclude his role as Chief Operating Officer and as the Company’s principal financial officer, effective May 15, 2023. Mr. Blaustein is expected to remain engaged with the Company as a strategic advisor.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on FNCH:
- Finch enters CP101 clinical trial agreement with Brigham and Women’s Hospital
- Finch Therapeutics Announces Clinical Collaboration in Ulcerative Colitis with Brigham and Women’s Hospital and Updates to University of Minnesota License Agreement
- Finch Therapeutics price target lowered to $7 from $17 at H.C. Wainwright
- Finch Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updates
